Information about serum FLC measurement in 
nonsecretory myeloma, monoclonal light chain diseases, and reference populations is reported in the literature (1-5,7), but there is limited data about FLCs in renal disease, monoclonal gammopathy of undetermined significance (MGUS), and myeloma patients after autologous stem cell transplants.